Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
27.57
-0.26 (-0.93%)
At close: Jun 9, 2025, 4:00 PM
27.59
+0.02 (0.05%)
After-hours: Jun 9, 2025, 7:57 PM EDT
Viking Therapeutics Stock Forecast
Stock Price Forecast
According to 12 professional analysts, the 12-month price target for Viking Therapeutics stock ranges from a low of $30 to a high of $138. The average analyst price target of $84 forecasts a 204.68% increase in the stock price over the next year.
Price Target: $84.00 (+204.68%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 28, 2025.
Analyst Ratings
The average analyst rating for Viking Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 6 | 4 | 4 | 4 |
| Buy | 4 | 5 | 5 | 6 | 6 | 6 |
| Hold | 0 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 14 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $104 | Buy | Initiates | $104 | +277.22% | Apr 28, 2025 |
| Truist Securities | Truist Securities | Strong Buy Reiterates $95 → $75 | Strong Buy | Reiterates | $95 → $75 | +172.03% | Apr 28, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $105 → $102 | Buy | Maintains | $105 → $102 | +269.97% | Apr 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $102 | Strong Buy | Reiterates | $102 | +269.97% | Apr 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $102 | Strong Buy | Reiterates | $102 | +269.97% | Apr 17, 2025 |
Financial Forecast
Revenue This Year
n/a
from 706.68M
Revenue Next Year
n/a
EPS This Year
-1.93
from -1.01
EPS Next Year
-2.62
from -1.93
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.3M | 97.9M | 292.9M | ||
| Avg | 1.5M | 6.6M | 28.2M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -96.3% | 6,424.0% | 4,351.3% | ||
| Avg | -99.8% | 338.6% | 328.9% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.55 | -1.86 | -1.80 | ||
| Avg | -1.93 | -2.62 | -3.04 | ||
| Low | -2.52 | -3.93 | -4.19 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.